- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Vor Biopharma: Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 56 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective... ► Artikel lesen | |
| Mo | Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market | 2 | Benzinga.com | ||
| Mo | Vor Biopharma stock rating upgraded to Buy by H.C. Wainwright on telitacicept deal | 2 | Investing.com | ||
| Mo | Vor Biopharma: H.C. Wainwright stuft Aktie nach Telitacicept-Deal auf "Kaufen" hoch | 9 | Investing.com Deutsch | ||
| 26.06. | Vor Biopharma Stock Soars 73% On $175 Mln Private Placement Deal | 3 | RTTNews | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 26.06. | Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in Funding | 2 | MedCity News | ||
| 26.06. | Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions | 2 | FiercePharma | ||
| 26.06. | Vor Bio surges after private placement, licensing deal | 2 | Seeking Alpha | ||
| 26.06. | Vor Biopharma stock soars after licensing deal for autoimmune therapy | 3 | Investing.com | ||
| 26.06. | Stifel maintains hold rating on Vor Biopharma stock amid strategic shift | 1 | Investing.com | ||
| 26.06. | Vor Bio revives, thanks to $4bn+ licensing deal with RemeGen | 3 | pharmaphorum | ||
| 26.06. | Pre-market Movers: Vor Biopharma, Worthington Steel, Surf Air Mobility, Nano Labs, Protagenic Therapeutics | 366 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the Green Vor Biopharma Inc. (VOR) is up over 109% at $1.16.
Worthington... ► Artikel lesen | |
| 26.06. | Why Vor Bio Is Rising In Pre-market? | 5 | RTTNews | ||
| 26.06. | China's RemeGen Inks USD4.1 Billion Autoimmune Disorders Drug Deal With US' Vor Bio | 11 | Yicai Global | ||
| 26.06. | Vor Bio secures global rights to RemeGen autoimmune drug with $175M funding | 3 | Investing.com | ||
| 26.06. | Vor Bio sichert sich globale Rechte an RemeGen-Autoimmunmedikament mit 175 Mio. US-Dollar Finanzierung | 28 | Investing.com Deutsch | ||
| 26.06. | REMEGEN Grants Vor Bio Exclusive Development Rights for Telitacicept Outside Greater China | 1 | AASTOCKS | ||
| 26.06. | Vor Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.06. | Vor Bio secures $175 million in private placement financing | 2 | Investing.com | ||
| 25.06. | Vor Bio announces $175M private placement | 1 | Seeking Alpha |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NUVALENT | 80,50 | 0,00 % | Goldman Sachs nimmt Nuvalent-Aktie mit Kaufempfehlung in die Bewertung auf | ||
| RECURSION PHARMACEUTICALS | 5,210 | 0,00 % | Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? | ||
| CG ONCOLOGY | 26,680 | +1,25 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| BEAM THERAPEUTICS | 19,890 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Beam Therapeutics mit Kursziel von 80 US-Dollar | ||
| ENLIVEN THERAPEUTICS | 20,640 | +5,04 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress | Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
| TREVI THERAPEUTICS | 5,980 | 0,00 % | Cantor Fitzgerald initiates coverage on Trevi Therapeutics stock with Overweight rating | ||
| PHATHOM PHARMACEUTICALS | 8,910 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 22,650 | 0,00 % | Revolution Medicines, Inc.: Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors | REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 13,010 | +1,48 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
| TANGO THERAPEUTICS | 5,650 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung ... | BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines... ► Artikel lesen | |
| IMMUNOME | 8,630 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
| HARMONY BIOSCIENCES | 32,110 | 0,00 % | Pre-market Movers: Alti Global, CXApp, PAM Transportation Services, Harmony Biosciences, iCoreConnect | ROME (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 09.15 A.M. ET).In the Green CXApp Inc (CXAI) is up over 37% at $1.11.
PAM Transportation... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 2,920 | 0,00 % | Morgan Stanley initiates Sana Biotechnology stock with Overweight rating | ||
| RELAY THERAPEUTICS | 3,600 | +2,27 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 | Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Data continue to support... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 44,370 | +0,11 % | Guggenheim reiterates Buy on Apogee Therapeutics stock ahead of key data |
VOR BIOPHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,450 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.